{"id":947973,"date":"2026-03-31T11:18:40","date_gmt":"2026-03-31T15:18:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/"},"modified":"2026-03-31T11:18:40","modified_gmt":"2026-03-31T15:18:40","slug":"lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/","title":{"rendered":"LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program"},"content":{"rendered":"

\nDelivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD\u2019s collaboration with Novo Nordisk
\n<\/h2>\n
\n

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc.<\/u><\/a> (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk’s new Wegovy\u00ae (semaglutide) subscription program \u2014 the first and only GLP-1 subscription offering of its kind \u2014 now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings.<\/p>\n

The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy\u00ae program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations and $600 for oral therapy.<\/p>\n

“Our inclusion in the Wegovy\u00ae subscription program is a natural extension of our established relationship with Novo Nordisk,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “This program deepens the value of our collaboration and adds meaningful financial savings for the patients we serve. By integrating subscription pricing with our comprehensive remote patient care model, we’re delivering the future of obesity treatment \u2014 branded therapy that is more accessible, affordable, and clinically supported.”<\/p>\n

Since its launch in 2025, LifeMD’s collaboration with Novo Nordisk has expanded from an initial NovoCare\u00ae Pharmacy integration into a multi-faceted commercial collaboration spanning injectable and oral Wegovy\u00ae and Ozempic\u00ae. LifeMD is recognized as a telehealth provider on both the NovoCare\u00ae and Wegovy\u00ae websites \u2014 a distinction that underscores the depth and durability of the relationship.<\/p>\n

Patients accessing Wegovy through LifeMD benefit from a comprehensive, end-to-end care experience that includes: virtual visits with LifeMD’s affiliated medical group across all 50 states; ongoing clinical oversight and care management; access to nationwide diagnostic testing; and simplified billing and payment.<\/p>\n

The Wegovy\u00ae subscription program is now available to eligible patients through LifeMD at https:\/\/lifemd.com\/weight-management\/<\/a>.<\/p>\n

\n About LifeMD, Inc.<\/strong>\n <\/p>\n

LifeMD\u00ae<\/sup> is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men\u2019s and women\u2019s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com<\/u><\/a>.<\/p>\n

\n Cautionary Note Regarding Forward Looking Statements<\/strong>\n <\/p>\n

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201ccontinue,\u201d and \u201cpotential,\u201d or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.<\/p>\n

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, \u201cRisk Factors\u201d identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.<\/p>\n

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.<\/p>\n

\n Investor Contact<\/strong>
\n
Atul Kavthekar, Chief Financial Officer
investors@lifemd.com<\/u><\/a><\/p>\n

\n Media Contact<\/strong>
\n
Jessica Friedeman, Chief Business Officer
press@lifemd.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD\u2019s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk’s new Wegovy\u00ae (semaglutide) subscription program \u2014 the first and only GLP-1 subscription offering of its kind \u2014 now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy\u00ae program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations … <\/p>\n

Continue reading “LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-947973","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLifeMD Offers Novo Nordisk's Industry-First Wegovy\u00ae Telehealth Subscription Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LifeMD Offers Novo Nordisk's Industry-First Wegovy\u00ae Telehealth Subscription Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD\u2019s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk’s new Wegovy\u00ae (semaglutide) subscription program \u2014 the first and only GLP-1 subscription offering of its kind \u2014 now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy\u00ae program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations … Continue reading "LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T15:18:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program\",\"datePublished\":\"2026-03-31T15:18:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/\"},\"wordCount\":830,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/\",\"name\":\"LifeMD Offers Novo Nordisk's Industry-First Wegovy\u00ae Telehealth Subscription Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=\",\"datePublished\":\"2026-03-31T15:18:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LifeMD Offers Novo Nordisk's Industry-First Wegovy\u00ae Telehealth Subscription Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/","og_locale":"en_US","og_type":"article","og_title":"LifeMD Offers Novo Nordisk's Industry-First Wegovy\u00ae Telehealth Subscription Program - Market Newsdesk","og_description":"Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD\u2019s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk’s new Wegovy\u00ae (semaglutide) subscription program \u2014 the first and only GLP-1 subscription offering of its kind \u2014 now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy\u00ae program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations … Continue reading \"LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-31T15:18:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program","datePublished":"2026-03-31T15:18:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/"},"wordCount":830,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/","name":"LifeMD Offers Novo Nordisk's Industry-First Wegovy\u00ae Telehealth Subscription Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=","datePublished":"2026-03-31T15:18:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTYyMiM3NTEyNjAzIzIwMTkzNTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lifemd-offers-novo-nordisks-industry-first-wegovy-telehealth-subscription-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LifeMD Offers Novo Nordisk’s Industry-First Wegovy\u00ae Telehealth Subscription Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=947973"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947973\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=947973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=947973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=947973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}